Bioxytran (BIXT) Change in Accured Expenses (2010 - 2026)
Bioxytran (BIXT) posted Change in Accured Expenses of $215868.0 for Q1 2026, up 208.34% sequentially from -$199257.0 in Q4 2025, and up 33.6% YoY from $161575.0 in Q1 2025.
Bioxytran (BIXT) Change in Accured Expenses (2010 - 2026) Analysis & Trends
Bioxytran has reported Change in Accured Expenses for 17 years, with the latest figure at $215868.0 in Q1 2026.
- Quarterly Change in Accured Expenses rose 33.6% year-over-year to $215868.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $550214.0 (up 162.92% YoY) and the FY2025 annual result came in at $495921.0, up 92.06% from the prior year.
- Change in Accured Expenses rose to $215868.0 in Q1 2026 per BIXT's latest filing, from -$199257.0 in the prior quarter.
- Over five years, Change in Accured Expenses peaked at $502372.0 in Q2 2024 and troughed at -$603795.0 in Q3 2024.
- A 5-year average of $52063.2 and a median of $72985.0 in 2025 frame the typical range for Change in Accured Expenses.
- The sharpest annual moves came in 2023 and 2024: Change in Accured Expenses plunged 1225.83% in 2023, then jumped 2736.44% in 2024.
- Over 5 years, Change in Accured Expenses stood at $412313.0 in 2022, then slumped by 101.37% to -$5656.0 in 2023, then surged by 2736.44% to $149117.0 in 2024, then sank by 233.62% to -$199257.0 in 2025, then surged by 208.34% to $215868.0 in 2026.
- According to Business Quant data, Change in Accured Expenses over the past three periods registered $215868.0, -$199257.0, and $72985.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Change in Accured Expenses (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | 222.50 Mn |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 492.70 Mn |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | 11.00 Mn |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 212.44 Mn |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 61.62 Mn |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | - |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | 68.82 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | Bioxytran | 2.52 Mn | 2.27 Mn | - | 133,181.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 215,868.00 |
| Mar 31, 2026 | 215,868.00 |
| Dec 31, 2025 | -199,257.00 |
| Dec 31, 2025 | -199,257.00 |
| Sep 30, 2025 | 72,985.00 |
| Sep 30, 2025 | 72,985.00 |
| Jun 30, 2025 | 460,618.00 |
| Jun 30, 2025 | 460,618.00 |
| Mar 31, 2025 | 161,575.00 |
| Mar 31, 2025 | 161,575.00 |
| Dec 31, 2024 | 149,117.00 |
| Dec 31, 2024 | 149,117.00 |
| Sep 30, 2024 | -603,795.00 |
| Sep 30, 2024 | -603,795.00 |
| Jun 30, 2024 | 502,372.00 |
| Jun 30, 2024 | 502,372.00 |
| Mar 31, 2024 | 210,512.00 |
| Mar 31, 2024 | 210,512.00 |
| Dec 31, 2023 | -5,656.00 |
| Dec 31, 2023 | -5,656.00 |